LYEL News and Press, Lyell Immunopharma Inc. From 09/28/22

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the exe...

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that a poster describing the first-in...

The following slide deck was published by Lyell Immunopharma, Inc. in conjunction with this event. For further details see: Lyell Immunopharma (LYEL) Investor Presentation - Slideshow

Lyell Immunopharma press release ( NASDAQ: LYEL ): Q2 net loss of $10.3M Revenue of $35.7M (+1257.4% Y/Y). For further details see: Lyell Immunopharma reports Q2 results

Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple product candidates through key clinical milestones SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Lye...

Gainers: Pliant Therapeutics ( PLRX ) +114% . Kaspien Holdings ( KSPN ) +99% . Iterum Therapeutics ( ITRM ) +83% . La Jolla Pharmaceutical Company ( LJPC ) +81% . Digital World Acquisition ( DWACW ) +51% . Volcon ( VLCN )...

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team w...

The following slide deck was published by Lyell Immunopharma, Inc. in conjunction with this event. For further details see: Lyell Immunopharma Investor Presentation - Slideshow

Lyell Immunopharma press release (NASDAQ:LYEL): Q1 Non-GAAP Net Loss of $50M Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 For further details see: Lyell Immunopharma reports Q1 results

Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipeline Research highlighting novel reprogramming technologies designed to overcome barriers to successful adoptive cell therapy in solid tumors present...